These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27756833)

  • 41. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
    Depoortère R; Dargazanli G; Estenne-Bouhtou G; Coste A; Lanneau C; Desvignes C; Poncelet M; Heaulme M; Santucci V; Decobert M; Cudennec A; Voltz C; Boulay D; Terranova JP; Stemmelin J; Roger P; Marabout B; Sevrin M; Vigé X; Biton B; Steinberg R; Françon D; Alonso R; Avenet P; Oury-Donat F; Perrault G; Griebel G; George P; Soubrié P; Scatton B
    Neuropsychopharmacology; 2005 Nov; 30(11):1963-85. PubMed ID: 15956994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex.
    Chen L; Yang CR
    J Neurophysiol; 2002 May; 87(5):2324-36. PubMed ID: 11976371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.
    Di Giovanni G; Svob Strac D; Sole M; Unzeta M; Tipton KF; Mück-Šeler D; Bolea I; Della Corte L; Nikolac Perkovic M; Pivac N; Smolders IJ; Stasiak A; Fogel WA; De Deurwaerdère P
    Front Neurosci; 2016; 10():541. PubMed ID: 27932945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders.
    Reuillon T; Ward SE; Beswick P
    Curr Top Med Chem; 2016; 16(29):3536-3565. PubMed ID: 27363568
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Frontal dysexecutive syndromes].
    Godefroy O; Brigitte A; Philippe A; Mira DH; Olivier G; Didier le G; Rose-Marie M; Thierry M; Chrystèle M; Blandine P; Bernard P; Philippe R;
    Rev Neurol (Paris); 2004 Oct; 160(10):899-909. PubMed ID: 15492716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From affective to cognitive processing: Functional organization of the medial frontal cortex.
    Simon J; Rudebeck PH; Rich EL
    Int Rev Neurobiol; 2021; 158():1-28. PubMed ID: 33785142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Executive control functions and neuropsychiatric disorders -- perspectives for research und clinical practice].
    Kaiser S; Mundt C; Weisbrod M
    Fortschr Neurol Psychiatr; 2005 Aug; 73(8):438-50. PubMed ID: 16052438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review.
    Pardo M; Cheng Y; Sitbon YH; Lowell JA; Grieco SF; Worthen RJ; Desse S; Barreda-Diaz A
    Neurosci Res; 2019 Dec; 149():1-13. PubMed ID: 30389571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.
    Li CT; Yang KC; Lin WC
    Front Psychiatry; 2018; 9():767. PubMed ID: 30733690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents.
    Vasiliu O
    Front Pharmacol; 2022; 13():884143. PubMed ID: 35774601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The treatment of depression - searching for new ideas.
    Stachowicz K; Sowa-Kućma M
    Front Pharmacol; 2022; 13():988648. PubMed ID: 36278184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.
    Darvesh AS; Carroll RT; Geldenhuys WJ; Gudelsky GA; Klein J; Meshul CK; Van der Schyf CJ
    Expert Opin Drug Discov; 2011 Feb; 6(2):109-127. PubMed ID: 21532928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computational perspectives on dopamine function in prefrontal cortex.
    Cohen JD; Braver TS; Brown JW
    Curr Opin Neurobiol; 2002 Apr; 12(2):223-9. PubMed ID: 12015241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Translating cognition from animals to humans.
    Keeler JF; Robbins TW
    Biochem Pharmacol; 2011 Jun; 81(12):1356-66. PubMed ID: 21219876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades.
    Machado-Vieira R; Zarate CA; Manji HK
    Curr Psychos Ther Rep; 2006 Dec; 4(4):181-190. PubMed ID: 25620894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The origin of 7alpha-hydroxy-dehydroepiandrosterone and its physiological role: a history of discoveries.
    Stárka L
    Physiol Res; 2017 Sep; 66(Suppl 3):S285-S294. PubMed ID: 28948812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systems biological approach on neurological disorders: a novel molecular connectivity to aging and psychiatric diseases.
    Ahmed SS; Ahameethunisa AR; Santosh W; Chakravarthy S; Kumar S
    BMC Syst Biol; 2011 Jan; 5():6. PubMed ID: 21226925
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.